Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin

American Journal of Cardiology

Volumn 87, Issue 5 SUPPL. 1, 2001, Pages 33-36

  Olsson, Anders G ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE CALCULATION; DRUG POTENCY; DRUG TOLERABILITY; DRUG UTILIZATION; HUMAN; HYPERCHOLESTEROLEMIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; TREATMENT OUTCOME;

EID: 0035825948     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(01)01455-2     Document Type: Conference Paper

References (27)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
7. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
8. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?
9. Cholesterol reduction yields clinical benefit: Impact of statin trials
10. Aggressive lipid-lowering therapy: A clinical imperative
11. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
12. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
13. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
14. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dL in patients with CHD
15. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
16. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
17. Drug treatment of lipid disorders
18. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
19. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
20. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
21. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
22. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial)
23. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
24. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
25. Pharmacological properties of ZD4522: A new HMG-CoA reductase inhibitor
26. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
27. Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia